-
Mashup Score: 3Novartis announces FDA approval of BEOVU® for the treatment of diabetic macular edema | Novartis United States of America - 2 year(s) ago
Published on Jun 01, 2022
Categories: Latest Headlines, OphthalmologyTweet
-
Mashup Score: 0NICE issues recommendation for Beovu for wet AMD - 3 year(s) ago
Ocular Surgery News Europe Edition | The U.K. National Institute for Health and Care Excellence has issued a final appraisal determination recommending Novartis’ brolucizumab treatment for wet age-related macular degeneration.The novel Beovu “could help minimize treatment burden, with more than 50% of patients maintained on 12-weekly dosing intervals immediately after the loading phase to week…
Source: www.healio.comCategories: Latest Headlines, OphthalmologyTweet-
NICE issues recommendation for Beovu for wet AMD #beovu #wetAMD https://t.co/JrClMjZfDh
-
-
Mashup Score: 0NICE issues recommendation for Beovu for wet AMD - 3 year(s) ago
The U.K. National Institute for Health and Care Excellence has issued a final appraisal determination recommending Novartis’ brolucizumab treatment for wet age-related macular degeneration.The novel Beovu “could help minimize treatment burden, with more than 50% of patients maintained on 12-weekly dosing intervals immediately after the loading phase to week 48,” the company said
Source: www.healio.comCategories: Latest Headlines, OphthalmologyTweet-
NICE issues recommendation for Beovu for wet AMD #beovu #wetAMD https://t.co/Kh0vtheqZs
-
-
Mashup Score: 0Beovu offers model on how to handle unexpected complications - 3 year(s) ago
Ocular Surgery News | Beovu, manufactured and distributed by Novartis, achieved FDA approval on Oct. 8, 2019.FDA approval was based on two extensive prospective randomized masked clinical trials named HAWK and HARRIER. These clinical trials included more than 1,800 patients enrolled and followed for 96 months in 400 centers globally by the world’s top retina specialists.
Source: www.healio.comCategories: Latest Headlines, OphthalmologyTweet-
Richard L. Lindstrom, MD, shares a perspective in the recent issue of Ocular Surgery News, read it now: https://t.co/uhqU5l5kIR #beovu #retina #antiVEGF https://t.co/lxJ3NNCUUF
-
-
Mashup Score: 1
Patients with diabetic macular edema treated with brolucizumab 6 mg demonstrated noninferiority in change in best corrected visual acuity compared with patients who received aflibercept 2 mg, according to the results of a phase 3 study.Novartis released data from the phase 3 KESTREL study, which assessed the safety and efficacy of Beovu (brolucizumab) 3 mg and 6 mg in DME. Patients in the
Source: www.healio.comCategories: Latest Headlines, OphthalmologyTweet-
Second phase 3 study shows good results for Beovu in DME treatment #dme #beovu https://t.co/tPE8E663oC
-
-
Mashup Score: 0Retina specialists receptive but cautious regarding use of Beovu - 3 year(s) ago
Ocular Surgery News | While further analysis of trial data confirms efficacy and safety events in real-world practice continue to be monitored, the attitude of retina specialists toward the newest FDA-approved anti-VEGF agent remains open but cautious.“Brolucizumab is, at this stage, a risk-benefit question,” Nancy M. Holekamp, MD, said.
Source: www.healio.comCategories: Latest Headlines, OphthalmologyTweet-
Check out the latest cover story from OSN online here: https://t.co/VWDSYVioJ5 #Ophthalmology #Retina #Beovu https://t.co/2F0zju4ers
-
-
Mashup Score: 0Ophthalmology Management - Rx Perspective – Beovu - 4 year(s) ago
BEOVU, from Novartis, reduces retinal fluid and provides long dosing intervals.
Source: Ophthalmology ManagementCategories: Latest Headlines, OphthalmologyTweet-
Rx Perspective: BEOVU, from @Novartis, is the first FDA-approved anti-VEGF to provide the ability to maintain wet AMD patients on a 3-month dosing interval immediately after a 3-month loading phase. #Ophthalmology #BEOVU https://t.co/d8rb5GfNzd https://t.co/gZz26D0SoZ
-
-
Mashup Score: 1Episode 227: ASRS ReST Report on Brolucizumab with Drs. Ajay Kuriyan, Shriji Patel, and Sarah Parker Read — Straight from the Cutter's Mouth - 4 year(s) ago
Drs. Ajay Kuriyan, Shriji Patel, and Sarah Parker Read join the podcast to discuss the American Society of Retinal Specialists recently released Research and Safety in Therapeutics Committee report on brolucizimab associated inflammation and vision loss. Relevant Financial Disclosures: Dr. Srid
Source: Straight from the Cutter's MouthCategories: OphthalmologyTweet-
RT @RetinaPodcast: https://t.co/Bfa1Jkyxat #beovu @asrsdocs @aao_ophth @vitreouscutter
-
-
Mashup Score: 0Brolucizumab’s safety under review - 4 year(s) ago
Novartis has launched a safety review of their new anti-VEGF agent brolucizumab (Beovu) following reports of possible unintended side effects after the drug was approved last October.
Categories: OphthalmologyTweet-
@aao_ophth issues statement about @Novartis #beovu #brolucizumab safety https://t.co/41HCLSYJCQ
-
-
Mashup Score: 0
Retina Specialist focuses on the latest advances in the diagnosis, medical management and surgical treatment of diseases of the retina, along with practical, real-world advice from leading clinicians and other experts on managing the successful retina practice.
Source: www.retina-specialist.comCategories: OphthalmologyTweet-
At the request of @RetSpecMag, @Novartis issues statement on reports of inflammation, vasculitis with #Beovu #brolucizumab Read it here: https://t.co/kQ3DzjB3Oz
-
US FDA Approves BEOVU 6mg for Diabetic Macular Edema đź’‰ Both clinical trials met the primary endpoint of non-inferiority in the change in BCVA from baseline at one year vs. aflibercept. https://t.co/u30HotumNF #diabetes #dme #beovu #eyecare #fdaapproval #fda #ophthalmology https://t.co/4qit2mblzV